RecruitingPhase 2NCT07256236

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

A Single-arm, Multicenter, Phase II Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination With QL1706 for Recurrent or Metastatic Cervical Cancer

Sponsor

Fujian Cancer Hospital

Enrollment

89 participants

Start Date

Jan 28, 2026

Study Type

INTERVENTIONAL

Conditions

Cervical Cancer

Summary

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called QL1706 and a drug called Sacituzumab tirumotecan for people with cervical cancer. The study is currently recruiting participants at 14 locations. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSacituzumab tirumotecan

intravenous (IV) infusion (4mg/kg, Q2W)

DRUGQL1706

intravenous (IV) infusion (3mg/kg, Q2W). Continuous administration will be maintained until radiological disease progression, occurrence of intolerable toxicity, the participant requests to discontinue treatment, or other treatment discontinuation criteria specified in the protocol are met (whichever occurs first). The maximum duration of administration for QL1706 is 24 months.

Locations(14)

Fujian Cancer Hospital

Fuzhou, Fujian, China

Fujian Medical University Affiliated Second Hospital

Fuzhou, Fujian, China

Zhangzhou Affiliated Hospital of Fujian Medical University

Zhangzhou, Fujian, China

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, China

The Second Hospital of Dalian Medical University

Dalian, Liaoning, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

The Second Qilu Hospital of Shandong University

Jinan, Shandong, China

Shandong Provincial Hospital

Jinan, Shandong, China

Cancer Hospital of Shandong First Medical University

Jinan, Shandong, China

Affiliated Hospital of Jining Medical University

Jining, Shandong, China

Qilu Hospital of Shandong University(Qingdao)

Qingdao, Shandong, China

Shanxi Cancer Hospital

Taiyuan, Shanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07256236

Related Trials

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

NCT075243225 locations

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

NCT06952660129 locations

Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana

NCT059521413 locations

DESTINY-PANTUMOUR04

NCT0712400018 locations

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703150 locations